Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double Blind, Double Dummy, Randomised, Multi-centre Study to Assess the Tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
Brief Summary: To evaluate vildagliptin as compared to gliclazide, given in combination with metformin in Muslim patients with type 2 diabetes fasting during Ramadan.


Options:
A: Arm Label: Low-dosage therapy; Type: EXPERIMENTAL; Interventions: Drug: Metformin and Glimepiride (Low Dosage), Drug: Metformin and Vildagliptin (Low Dosage), Drug: Metformin and Insulin Glargine U100 (Low Dosage), Drug: Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage) | Arm Label: Regular-dosage therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin and Glimepiride (Regular Dosage), Drug: Metformin and Vildagliptin (Regular Dosage), Drug: Metformin and Insulin Glargine U100 (Regular Dosage), Drug: Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage) | Intervention Type: DRUG; Name: Metformin and Glimepiride (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin and Vildagliptin (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin and Insulin Glargine U100 (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin, Insulin Glargine U100, and Human Regular Insulin (Low Dosage); Assigned to Arm(s): Low-dosage therapy | Intervention Type: DRUG; Name: Metformin and Glimepiride (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy | Intervention Type: DRUG; Name: Metformin and Vildagliptin (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy | Intervention Type: DRUG; Name: Metformin and Insulin Glargine U100 (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy | Intervention Type: DRUG; Name: Metformin, Insulin Glargine U100, and Human Regular Insulin (Regular Dosage); Assigned to Arm(s): Regular-dosage therapy
B: Arm Label: 14 days continuous glucose monitoring; Type: OTHER; Interventions: Other: Control period, Dietary Supplement: D-allulose period | Intervention Type: OTHER; Name: Control period; Assigned to Arm(s): 14 days continuous glucose monitoring | Intervention Type: DIETARY_SUPPLEMENT; Name: D-allulose period; Assigned to Arm(s): 14 days continuous glucose monitoring
C: Arm Label: Intervention; Type: OTHER; Interventions: Other: FAST | Arm Label: Control; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: FAST; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Control
D: Arm Label: Vildagliptin + placebo to Gliclazide; Type: EXPERIMENTAL; Interventions: Drug: Vildagliptin, Drug: Metformin, Drug: Placebo to Gliclazide | Arm Label: Gliclazide + placebo to Vildagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gliclazide, Drug: Metformin, Drug: Placebo to Vildagliptin | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Gliclazide; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin, Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Gliclazide; Assigned to Arm(s): Vildagliptin + placebo to Gliclazide | Intervention Type: DRUG; Name: Placebo to Vildagliptin; Assigned to Arm(s): Gliclazide + placebo to Vildagliptin

Answer: D